Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Combining non-pharmacological treatments with pharmacotherapies for PD

Joaquim Ferreira, MD, PhD, University of Lisbon, Lisbon, Portugal, discusses the use of levodopa as the most effective and safe drug for managing Parkinson’s disease (PD). Although there are common misconceptions about levodopa, it continues to be viewed as the first-line drug for the management of Parkinson’s motor symptoms. Prof. Ferreira emphasizes the importance of combining pharmacological and non-pharmacological treatments, including physical activity, socialization, and multi-disciplinary interventions to improve patient outcomes. A comprehensive approach to treatment is the new standard in managing PD. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


J.J.F received grants from GlaxoSmithKline, Grunenthal, Fundação MSD (Portugal), TEVA, MSD, Allergan, Novartis, Medtronic and Angelini. Received consultancy and speaker fees and participated in advisory boards for GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, BIAL, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion Pharmaceuticals, Zambon, Affiris, Roche, ONO and SK Chemicals.